Cytokine traps: multi-component, high-affinity blockers of cytokine action - Wikidata - wikimedia - TriplyDB

Cytokine traps: multi-component, high-affinity blockers of cytokine action

Cytokine traps: multi-component, high-affinity blockers of cytokine action

http://www.wikidata.org/entity/Q28217681

about

sameAs

Interventions for reducing inflammation in familial Mediterranean fever Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion Interventions for reducing inflammation in familial Mediterranean fever Canakinumab Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics The emerging role of biotechnological drugs in the treatment of gout IL-1 receptor 2 (IL-1R2) and its role in immune regulation Mechanisms of age-related macular degeneration The PYRIN domain in signal transduction IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model.A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy A receptor fusion protein for the inhibition of murine oncostatin M.Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation Lack of interleukin-1 signaling results in perturbed early vein graft wall adaptations.Evidence for anti-VEGF treatment of diabetic macular edema.Co-opting biology to deliver drugs An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis.Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Inhibition of tumor growth and angiogenesis by soluble EphB4.Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow.Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.Ocular complications of diabetes mellitus.Cytokine-based immunointervention in the treatment of autoimmune diseases.Potential new drugs for therapy of chronic obstructive pulmonary disease.Role for interleukin-1 beta in Trypanosoma cruzi-induced cardiomyocyte hypertrophy.Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment Drug development for asthma.Pharmacotherapy for treatment of retinal vein occlusion.The cytokine receptor gp130: faithfully promiscuous.Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS).Emerging treatments for asthma.Therapeutic potential of targeting IL-1 and IL-18 in inflammation.The selection of high-producing cell lines using flow cytometry and cell sorting.Blocking IL-1 in systemic inflammation Systems Based Study of the Therapeutic Potential of Small Charged Molecules for the Inhibition of IL-1 Mediated Cartilage Degradation

P2860

Q24187197-B209674F-F8D6-4F93-8632-03D132FE229E Q24194783-99B2B3D7-E715-412B-BE2A-AC68A305B0C6 Q24201537-FCD2A886-BF18-4572-92DE-DA591D937593 Q24642193-6D91EE20-55A4-4F96-A394-546BEABA904E Q26769935-56787104-DD68-4A7B-AD55-4FEDC926E297 Q26771522-86BDA60A-9E9F-483C-A4A5-460527AEE361 Q26822421-0B6474C1-8C81-40A0-BFD9-4394A226B224 Q26825459-9C1395F7-D2AB-400A-ACE8-8B962135562B Q26826872-C52556FF-C7F3-40C1-B620-21E398277FC1 Q27000182-6371E4CF-74D2-4904-BB99-D92A28CDCF35 Q28383855-C327E967-0615-4122-8864-666214F2F025 Q28585033-57586BD5-63F5-4CA2-9DAF-042A42BED8A1 Q33479625-DA6989F4-DED4-40B9-B9E0-EC499A692E3F Q33573612-D06847B1-1D81-4749-B23E-F0776C431282 Q33790462-A7E7378D-5EB7-4553-800B-0D700205D60A Q34167205-DFC6B3B7-A0F4-4E5D-A972-CFE4D96D4B1F Q34361972-790A4012-7139-4DE0-BA6C-A4BF24109E14 Q34385961-BB09DF3C-572F-4A87-9C00-0CE01829FE22 Q34424045-184C5C18-7C7A-478D-B081-CE53C2382E94 Q34439798-4799524D-6BF4-46AF-B5D7-BAC0E4466D47 Q34493943-57CEF25D-C5A7-460C-BEA1-FE435F600448 Q34658699-127071CF-87BA-4DD4-98A1-7238DE1FC6DB Q34770033-9351978E-363C-4B2A-A533-C7918559A092 Q34896866-17E00AA3-14D6-4FD4-B4E2-8554F1A7B40D Q34947216-BA379A1C-F34D-4C76-A4CD-7401CE5BB63D Q35041117-EA81BD7E-155D-447E-830F-5A83150C298D Q35049903-0316E007-D49F-4E68-9BF3-398A1034C99C Q35109131-BE99AA38-F1A2-4FEE-AF83-72D3E7FD0BC4 Q35164728-0A0A4995-E1FC-4694-8E03-75EC824DEAD7 Q35164934-A0C2A4F1-EFBF-40A9-A74D-4F97E7DD0A1B Q35165663-5CA2BCFA-D657-41D0-BCB6-FE1356A8C877 Q35183997-DB5F96CB-68D5-40B4-9B87-01DA6F07A67E Q35238943-7B05EF09-0FEA-4240-A836-E6B2AE3A6C2E Q35541851-E342AC9D-137D-4B44-BD38-75ECD2FDCEE2 Q35557377-9ACFD41C-DF5C-44FA-AC78-0BDE578AC483 Q35581140-0620D4CC-DFF1-4FD6-BCA9-033EF07C62DA Q35790840-C76261BE-9BB9-4E85-914B-01660783642F Q35925628-F92C2C5F-D71A-411F-AB7D-22CABCA93899 Q36113777-4B3A0FD6-9757-42BF-B631-E49AE22F0C3A Q36224923-3755B6FC-95A5-44FB-B7F0-AD034FF9F3AD

P2860

Cytokine traps: multi-component, high-affinity blockers of cytokine action

http://www.wikidata.org/entity/Q28217681

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@ast

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@en

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@nl

type

label

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@ast

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@en

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@nl

prefLabel

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@ast

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@en

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@nl

P1433

Q28217681-8EED9437-7792-42AB-B9CF-6790FD6E0E70

P1476

Q28217681-2D137D6D-B13F-45CF-9988-3D40475D93DF

P2093

Q28217681-1AAF11EB-DA96-4370-8A44-4C99D3EEB7C0

Q28217681-20A3868F-5680-40ED-8D66-42A8143A8D2E

Q28217681-3530BAF2-E907-4246-82BD-9C1F1F26D446

Q28217681-3882B460-3C79-4B56-B448-33A956EF97AA

Q28217681-40573F4F-07B6-4317-B540-E35A6A7247DB

Q28217681-4AC27F84-7FAE-4A7E-89E1-EF4F24D951B4

Q28217681-4E1A31E1-A395-4DA0-8BAC-19B4B9202D86

Q28217681-4ED7DBEE-30DE-49A3-83E1-970759537923

Q28217681-710F14C8-D9D9-4C18-9FF4-4EA2F2C3CEE2

Q28217681-84CDDDF1-68D4-48A7-B817-11EE75C577FD

P2860

Q28217681-040CC76C-2844-4A82-A053-E8E3AE571AB9

Q28217681-378DD99E-3C01-45ED-BB2F-813B3B205128

Q28217681-6DA87C28-23D2-4B3C-B0B5-FFCE9B424246

P2888

Q28217681-5488DDDC-A079-48F2-8644-8F698A405930

P304

Q28217681-2955C9C9-B514-47EB-A333-BDFCCC3280C8

P31

Q28217681-6558A51A-3A8F-434E-A354-1210ED00C01F

P356

Q28217681-3F62029E-1CC6-42E0-B1DD-A9084EC3E476

P407

Q28217681-339B4CFE-48B5-4AB3-9EBE-581E7655A7F0

P433

Q28217681-4735E0B8-8846-4B63-BC89-5D01285A7B96

P478

Q28217681-CB62763E-A19A-4939-8F3D-5AF30B3F8B87

P50

Q28217681-250E52F8-9455-4A02-B3F6-78B62C185108

P577

Q28217681-EA428755-2465-4936-8E4C-E516ABA95E72

P5875

Q28217681-E9CCA2A4-8912-46D1-8F28-D130712867DA

P6179

Q28217681-D3655DD3-3C86-4807-AF89-AEFF61B3E438

P698

Q28217681-4B1AA224-B3BB-40F0-A974-11398C71E854

P356

P1433

Nature Medicine

P1476

Cytokine traps: multi-component, high-affinity blockers of cytokine action

@en

P2093

Christopher Hartnett

http://www.w3.org/2001/XMLSchema#string

Czeslaw Radziejewski

http://www.w3.org/2001/XMLSchema#string

Ellen M Koehler-Stec

http://www.w3.org/2001/XMLSchema#string

Erica A Pyles

http://www.w3.org/2001/XMLSchema#string

Frank Lee

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

James P Fandl

http://www.w3.org/2001/XMLSchema#string

Jennifer McNay

http://www.w3.org/2001/XMLSchema#string

John S Rudge

http://www.w3.org/2001/XMLSchema#string

Kevin Bailey

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130

Interleukin-13: central mediator of allergic asthma

P2888

P304

47-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM811

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Aris Economides

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10990311

http://www.w3.org/2001/XMLSchema#string

P6179

1000828617

http://www.w3.org/2001/XMLSchema#string

P698

12483208

http://www.w3.org/2001/XMLSchema#string